|
|
Post by wyattdog on Feb 17, 2022 16:58:16 GMT -5
|
|
|
|
Post by thekid2499 on Feb 18, 2022 11:22:04 GMT -5
Thanks for providing the link. I listened to the call and my biggest takeaway is Mike doesn't see much changing from the Afrezza sales front in the near term. They are reducing spend around Afrezza, shifting some of the spend around, and are de-prioritizing it to some extent as they focus more on the other TS opportunities (#1 being Tyvaso DPI).
|
|
|
|
Post by radgray68 on Feb 18, 2022 12:05:58 GMT -5
I like that he still believes wholeheartedly in Afrezza but this talk was the most sobering guidance he's ever given on the marketing side. Great, game-changing drug if dosed right. Maybe even the future standard of care. However, the medical world is going to make us prove it first.
In the meantime, we have several other moneymaking opportunities to pursue........thank heavens. I fear, though, that the stock market is going to kick us around a little in the near term.
|
|
